Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis

References

• Siegel RL, Miller KD, Fuchs HE, et al., Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1): 7–33.
   PubMed Web of Science ®Google Scholar
• Wang YZ, Hu Y. Age-period-cohort analysis on kidney cancer mortality trend in China, 1992-2016. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42(3):508–512.
   PubMedGoogle Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
   PubMed Web of Science ®Google Scholar
• Bardelli A, Pantel K. Liquid biopsies, what we do not know (Yet). Cancer Cell. 2017;31(2):172–179.
   PubMed Web of Science ®Google Scholar
• Lakes J, Arsov C. PSA-screening und molekulare marker [PSA screening and molecular markers]. Urologe A. 2019;58(5):486–493.
   PubMedGoogle Scholar
• Yajima S, Nakanishi Y, Matsumoto S, et al. Prognostic significance of the postoperative/preoperative serum CEA level ratio in patients with solitary adrenal metastasis from lung cancer. Mol Clin Oncol. 2022;16(1):10.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q. Alpha-fetoprotein and hepatocellular carcinoma immunity. Can J Gastroenterol Hepatol. 2018;2018:9049252.
   PubMed Web of Science ®Google Scholar
• Tutar Y. Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429.
   PubMed Web of Science ®Google Scholar
• Mei Q, Li X, Guo M, et al. The miRNA network: micro-regulator of cell signaling in cancer. Expert Rev Anticancer Ther. 2014;14(12):1515–1527.
   PubMed Web of Science ®Google Scholar
• Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008;319(5871):1785–1786.
   PubMed Web of Science ®Google Scholar
• Shen S, Zhang S, Liu P, et al. Potential role of microRNAs in the treatment and diagnosis of cervical cancer. Cancer Genet. 2020;248-249:25–30.
   PubMed Web of Science ®Google Scholar
• Eissa S, Matboli M, Hegazy MG, et al. Evaluation of urinary microRNA panel in bladder cancer diagnosis: relation to bilharziasis. Transl Res. 2015;165(6):731–739.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC. Misunderstandings about Q and ‘Cochran’s Q test’ in meta-analysis. Stat Med. 2016;35(4):485–495.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882–893.
   PubMed Web of Science ®Google Scholar
• Caraguel CG, Vanderstichel R. The two-step Fagan’s nomogram: ad hoc interpretation of a diagnostic test result without calculation. Evid Based Med. 2013;18(4):125–128.
   PubMedGoogle Scholar
• Chen X, Lou N, Ruan A, et al. miR-224/miR-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. Oncol Lett. 2018;16(2):1666–1674.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44(1):53–58.
   PubMed Web of Science ®Google Scholar
• Kalogirou C, Ellinger J, Kristiansen G, et al. Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. Transl Androl Urol. 2020;9(3):1314–1322.
   PubMed Web of Science ®Google Scholar
• Li G, Zhao A, Péoch M, et al. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma. Urol Oncol. 2017;35(5):294–299.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ni M, Su Y, et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur Urol Focus. 2018;4(3):412–419.
   PubMedGoogle Scholar
• Zhao A, Li G, Péoc’h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94(1):115–120.
   PubMed Web of Science ®Google Scholar
• Li D, Shu B, Tang S, et al. Expresion of plasma miR-210 and miR-378 and theirs clinical significance in renal clear cel carcinoma. Clin Urol (China). 2015;30(10): 897–901
   Google Scholar
• Wang X, Yang J, Chen C, et al. Serum exosomal miR-210 as a noninvasive molecular diagnosis biomarker in clear cell renal cell carcinoma. Chin J Urol. 2017;38(9): 707–711
   Google Scholar
• Bi X, Niu Y, Hulaxi D, et al. The expression and clinical significances of miRNA-378 in serum of patients with renal clear cell carcinoma. J Xinjiang Med Univ (China). 2015;38(5): 608–611
   Google Scholar
• Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10(1):55.
   PubMed Web of Science ®Google Scholar
• Yang Y, Abudu R, Mulati R, et al. Expression of serum miRNA-378 in renal cell carcinoma patients and its clinical significance. Clin Misdiagnosis Mistherapy (China). 2015;28(3): 93–96
   Google Scholar
• Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011;6(9):e25787.
   PubMed Web of Science ®Google Scholar
• Yadav S, Khandelwal M, Seth A, et al. Serum microRNA expression profiling: potential diagnostic implications of a panel of serum microRNAs for clear cell renal cell cancer. Urology. 2017;104:64–69.
   PubMed Web of Science ®Google Scholar
• Chen X, Li R, Li X, et al. Identification of a four-microRNA panel in serum for screening renal cell carcinoma. Pathol Res Pract. 2021;227:153625.
   PubMed Web of Science ®Google Scholar
• Guan J. Analysis of serum mi R-21 and mi R-106a expression in patients with renal cell carcinoma and its clinical values. China: Xinjiang Medical University; 2016.
   Google Scholar
• Yang Y, Abudu R, Mulati R, et al. Differential expression of serum miRNA-21 in patients with renal cell carcinoma before and after surgery and its significance. Hainan Med J (China). 2015;26(7): 948–951
   Google Scholar
• Chen J, Chen Y, Gu L, et al. LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2016;7(45):74325–74336.
   PubMedGoogle Scholar
• Lommen K, Vaes N, Aarts MJ, et al. Diagnostic DNA methylation biomarkers for renal cell carcinoma: a systematic review. Eur Urol Oncol. 2021;4(2):215–226.
   PubMed Web of Science ®Google Scholar
• Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671–681.
   PubMed Web of Science ®Google Scholar
• Fasanaro P, D’Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283(23):15878–15883.
   PubMed Web of Science ®Google Scholar
• Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35(6):856–867.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun H, Dai H, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle. 2009;8(17):2756–2768.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu H. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients. J Clin Lab Anal. 2020;34(6):e23237.
   PubMed Web of Science ®Google Scholar
• Tao J, Ji J, Li X, et al. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget. 2015;6(9):6977–6988.
   PubMedGoogle Scholar
• Tan D, Zhou C, Han S, et al. MicroRNA-378 enhances migration and invasion in cervical cancer by directly targeting autophagy-related protein 12. Mol Med Rep. 2018;17(5):6319–6326.
   PubMed Web of Science ®Google Scholar
• Zhong W, Peng H, Tian A, et al. Expression of miRNA-1233 in placenta from patients with hypertensive disorder complicating pregnancy and its role in disease pathogenesis. Int J Clin Exp Med. 2015;8(6):9121–9127.
   PubMed Web of Science ®Google Scholar
• Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A, et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids. 2020;20:409–420.
   PubMedGoogle Scholar
• Dai L, Chen F, Zheng Y, et al. miR-21 regulates growth and EMT in lung cancer cells via PTEN/Akt/GSK3β signaling. Front Biosci (Landmark Ed). 2019;24(8):1426–1439.
   PubMed Web of Science ®Google Scholar
• Lv D, Bi Q, Li Y, et al. Long non-coding RNA MEG3 inhibits cell migration and invasion of non-small cell lung cancer cells by regulating the miR-21-5p/PTEN axis. Mol Med Rep. 2021;23(3):191.
   PubMed Web of Science ®Google Scholar
• Cimadamore A, Massari F, Santoni M, et al. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Rev Mol Diagn. 2020;20(2):141–150.
   PubMed Web of Science ®Google Scholar
• Fasanella D, Antonaci A, Esperto F, et al. Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review. Diagnosis (Berl). 2021:000010151520210080.
   Google Scholar